Dynavax jumps AH on HEPLISAV Phase 3 data

|About: Dynavax Technologies Corporation (DVAX)|By:, SA News Editor

Shares of Dynavax (DVAX) jump 5.9% AH after the company announces the previously published results of 2 Phase 3 trials of its HEPLISAV hepatitis B vaccine.

Results from over 2,400 subjects aged 40-70 led the authors to conclude that the vaccine "induced significantly higher seroprotection rates in all groups (including hyporesponsive populations) than the licensed comparator hepatitis B vaccine ... while maintaining a similar safety profile."

The second trial in over 500 participants with chronic kidney disease determined that HEPLISAV provided "significantly higher seroprotection rates and earlier and more persistent seroprotection than the licensed conparator ... while maintaining a similar safety profile."